Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease

D. Grahame Hardie; Peter Tontonoz; Laszlo Nagy

doi:10.1016/j.febslet.2007.11.018

Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease

D. Grahame Hardie, Peter Tontonoz (Editor), Laszlo Nagy (Editor)

Research output: Contribution to journal › Review article › peer-review

197 Citations (Scopus)

Abstract

Obesity, type 2 diabetes and the metabolic syndrome are disorders of energy balance, which the AMP-activated protein kinase (AMPK) regulates both at the cellular and whole body levels. AMPK switches cells from an anabolic state where nutrients are taken up and stored, to a catabolic state where they are oxidized. Drugs that activate AMPK indirectly (metformin and thiazolidinediones) are now the mainstay of treatment for type 2 diabetes, but more direct AMPK activators may have fewer side effects. However, activating mutations in AMPK can cause heart disease, and it will be important to look for adverse effects in the heart. (C) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Original language	English
Pages (from-to)	81-89
Number of pages	9
Journal	FEBS Letters
Volume	582
Issue number	1
DOIs	https://doi.org/10.1016/j.febslet.2007.11.018
Publication status	Published - 9 Jan 2008

Keywords

AMP-activated protein kinase
metabolic syndrome
diabetes
metformin
thiazolidinedione
ventricular pre-excitation
FATTY-ACID OXIDATION
SKELETAL-MUSCLE
INSULIN-RESISTANCE
GLUCOSE-TRANSPORT
5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE
RESPIRATORY-CHAIN
UPSTREAM KINASE
FOOD-INTAKE
C-ELEGANS
COMPLEX I

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.febslet.2007.11.018

Cite this

@article{13eee145c40f4e8ba88b5dc9e445195c,

title = "Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease",

abstract = "Obesity, type 2 diabetes and the metabolic syndrome are disorders of energy balance, which the AMP-activated protein kinase (AMPK) regulates both at the cellular and whole body levels. AMPK switches cells from an anabolic state where nutrients are taken up and stored, to a catabolic state where they are oxidized. Drugs that activate AMPK indirectly (metformin and thiazolidinediones) are now the mainstay of treatment for type 2 diabetes, but more direct AMPK activators may have fewer side effects. However, activating mutations in AMPK can cause heart disease, and it will be important to look for adverse effects in the heart. (C) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.",

keywords = "AMP-activated protein kinase, metabolic syndrome, diabetes, metformin, thiazolidinedione, ventricular pre-excitation, FATTY-ACID OXIDATION, SKELETAL-MUSCLE, INSULIN-RESISTANCE, GLUCOSE-TRANSPORT, 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE, RESPIRATORY-CHAIN, UPSTREAM KINASE, FOOD-INTAKE, C-ELEGANS, COMPLEX I",

author = "Hardie, {D. Grahame} and Peter Tontonoz and Laszlo Nagy",

year = "2008",

month = jan,

day = "9",

doi = "10.1016/j.febslet.2007.11.018",

language = "English",

volume = "582",

pages = "81--89",

journal = "FEBS Letters",

issn = "0014-5793",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease

AU - Hardie, D. Grahame

A2 - Tontonoz, Peter

A2 - Nagy, Laszlo

PY - 2008/1/9

Y1 - 2008/1/9

N2 - Obesity, type 2 diabetes and the metabolic syndrome are disorders of energy balance, which the AMP-activated protein kinase (AMPK) regulates both at the cellular and whole body levels. AMPK switches cells from an anabolic state where nutrients are taken up and stored, to a catabolic state where they are oxidized. Drugs that activate AMPK indirectly (metformin and thiazolidinediones) are now the mainstay of treatment for type 2 diabetes, but more direct AMPK activators may have fewer side effects. However, activating mutations in AMPK can cause heart disease, and it will be important to look for adverse effects in the heart. (C) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

AB - Obesity, type 2 diabetes and the metabolic syndrome are disorders of energy balance, which the AMP-activated protein kinase (AMPK) regulates both at the cellular and whole body levels. AMPK switches cells from an anabolic state where nutrients are taken up and stored, to a catabolic state where they are oxidized. Drugs that activate AMPK indirectly (metformin and thiazolidinediones) are now the mainstay of treatment for type 2 diabetes, but more direct AMPK activators may have fewer side effects. However, activating mutations in AMPK can cause heart disease, and it will be important to look for adverse effects in the heart. (C) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

KW - AMP-activated protein kinase

KW - metabolic syndrome

KW - diabetes

KW - metformin

KW - thiazolidinedione

KW - ventricular pre-excitation

KW - FATTY-ACID OXIDATION

KW - SKELETAL-MUSCLE

KW - INSULIN-RESISTANCE

KW - GLUCOSE-TRANSPORT

KW - 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE

KW - RESPIRATORY-CHAIN

KW - UPSTREAM KINASE

KW - FOOD-INTAKE

KW - C-ELEGANS

KW - COMPLEX I

U2 - 10.1016/j.febslet.2007.11.018

DO - 10.1016/j.febslet.2007.11.018

M3 - Review article

C2 - 18022388

SN - 0014-5793

VL - 582

SP - 81

EP - 89

JO - FEBS Letters

JF - FEBS Letters

IS - 1

ER -

Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this